Phase III study of Erlotinib vs. observation in ovarian cancer
Can a new drug called Erlotinib help stop Ovarian Cancer coming back?
What was this study about?
This trial was run by the European Organisation for Research and Treatment of Cancer (EORTC) across Europe and was looking to see whether a drug called 'Erlotinib' reduced the time to relapse of ovarian cancer (or extended survival) in women who were previously diagnosed and treated for ovarian cancer and were currently free of disease.
What difference did this study make?
The trial concluded that taking maintenance erlotinib after first line chemotherapy in patients with ovarian, peritoneal or fallopian tube cancer did not increase time to progression of disease or extend life. The drug caused some side effects and approximately 25% of the patients stopped the treatment due to these (mainly rash).
Type of study
Who funded the study?
This trial was funded by the drug company, Roche.
When did it take place?
The trial closed to recruitment in February 2008.
Where did it take place?
This study took place in hospitals across the UK.
Who was included?
Women who had finished their ovarian cancer treatment in the last 6 weeks.